Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man study. - Wikidata - wikimedia - TriplyDB

Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man study.

Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man study.

http://www.wikidata.org/entity/Q34209528

about

Use of Inotropic Agents in Treatment of Systolic Heart Failure Signaling effectors underlying pathologic growth and remodeling of the heart Force generation by kinesin and myosin cytoskeletal motor proteins Ensemble force changes that result from human cardiac myosin mutations and a small-molecule effector Challenges in acute heart failure clinical management: optimizing care despite incomplete evidence and imperfect drugs Modelling sarcomeric cardiomyopathies in the dish: from human heart samples to iPSC cardiomyocytes Targeting the sarcomere to correct muscle function Potential new drug treatments for congestive heart failure.Translation of Cardiac Myosin Activation with 2-deoxy-ATP to Treat Heart Failure via an Experimental Ribonucleotide Reductase-Based Gene Therapy Cardiac myosin binding protein-C: a novel sarcomeric target for gene therapy 2-Deoxy adenosine triphosphate improves contraction in human end-stage heart failure.Acute decompensated heart failure update.The novel cardiac myosin activator omecamtiv mecarbil increases the calcium sensitivity of force production in isolated cardiomyocytes and skeletal muscle fibres of the rat Molecular effects of the myosin activator omecamtiv mecarbil on contractile properties of skinned myocardium lacking cardiac myosin binding protein-C Relative bioavailability, food effect, and safety of the single-dose pharmacokinetics of omecamtiv mecarbil following administration of different modified-release formulations in healthy subjects AAV6-mediated Cardiac-specific Overexpression of Ribonucleotide Reductase Enhances Myocardial Contractility.Pharmacological Strategies to Retard Cardiovascular Aging Incorporating development of a patient-reported outcome instrument in a clinical drug development program: examples from a heart failure program.Focal energy deprivation underlies arrhythmia susceptibility in mice with calcium-sensitized myofilaments.SERCA2a gene therapy in heart failure: an anti-arrhythmic positive inotrope.Hypertrophic and dilated cardiomyopathy: four decades of basic research on muscle lead to potential therapeutic approaches to these devastating genetic diseases.Developments in heart failure 2011.Inotropes for the management of acute heart failure patients with renal dysfunction. Still an option?Molecular targets of current and prospective heart failure therapies.What's new in the treatment of acute heart failure?Antagonist molecules in the treatment of angina End-stage heart failure non-pharmacological therapy: recent advances in pacemakers, pressure monitors, pumps and other devices.Heart failure highlights in 2012-2013.Novel drug targets in clinical development for heart failure.Inotropes and inodilators for acute heart failure: sarcomere active drugs in focus.Novel drug mechanisms in development for heart failure.Serelaxin : a potential new drug for the treatment of acute heart failure.New medical therapies for heart failure.Omecamtiv mecarbil: a new cardiac myosin activator for the treatment of heart failure.Emerging Therapies for Acute and Chronic Heart Failure: Hope or Hype?Long-term intravenous inotropes in low-output terminal heart failure?From Bench to Bedside: New Approaches to Therapeutic Discovery for Heart Failure The myosin activator omecamtiv mecarbil: a promising new inotropic agent.Cardiac Myosin Activators in Systolic Heart Failure: More Friend than Foe?Metabolic support for the heart: complementary therapy for heart failure?

P2860

Q26774435-793DCFCF-FC00-4AE8-B7DE-F609D3C354C5 Q26825154-10C3A1C4-FC07-4373-BD60-F3483542079A Q26827691-B6B11FF8-0671-404B-A5D2-29B9AE95F111 Q27320554-8D75B53C-A04F-4AF1-B474-B7F5F967A6D7 Q28085736-56812F0B-2F1B-40D9-BE6F-C7FBA38BF6A6 Q28255887-278FE16D-6A49-486A-9274-BC0854D8EA7E Q28260629-26A9D842-F625-4176-997F-95430AFD8C50 Q30251531-3DC31E27-6876-45DE-81A7-93CEA0538A81 Q33728779-7720672F-6AD4-45C9-A47E-4784FACA1513 Q34755677-0363ADD8-99C9-4724-ACCB-3F94BBD6BE93 Q34995668-67E8944E-2879-46BA-A436-348B348E62AA Q35139964-4417F1D1-68D8-4F6B-8736-F5ABA5AE735D Q36036237-8DBE13E7-BF72-410D-A40A-A0F9D6D82A16 Q36341946-738C2989-448A-493F-AC6D-ADD7D8D4D55C Q36645693-C0819588-7DC9-4B12-8976-8ED3991E9085 Q36756838-E84C1BCB-62D8-496D-943E-870D55033010 Q36972415-CD3D477C-3CD6-47BC-8486-7B069F8B59E3 Q37258267-E95CDD99-64DE-4A0D-B7E0-FB7E9A924B9B Q37363558-9920404A-E7D6-4FBD-9E3E-4138FF860E1D Q37418216-22577E0C-E0AA-464E-801E-120072BD6929 Q37701056-18F606B3-FD8E-4847-B10F-D8678BE77286 Q37995246-1A6BA1F4-BB9C-49F6-B281-D9A1D3369AE2 Q38061473-DCDE5B49-A13E-4B06-8CB6-E2F60F9354D2 Q38076688-025528B9-4F51-4326-AA39-B8150C152136 Q38123740-A510BC24-8533-4411-A67C-CFFFA209D307 Q38139089-BCC6BEC9-CC18-49CD-B4DA-2F34A4F7AE3D Q38179215-A2A1FC58-C921-4690-B85D-0E1BCAA8DDDA Q38182010-C51B3836-B0C5-473E-B122-05F010618780 Q38202895-534543BC-3232-4F3C-A951-BB0FDA5E3C34 Q38208442-702C92FC-F430-4B11-ADEE-7106B82DA5EA Q38209074-AB4E0EBA-3C5C-4090-8C7A-E0735B858327 Q38215304-5AD2AF15-A031-4B63-8EF1-414F27F448E1 Q38594785-C9A067F6-7C54-4629-A491-288B6AA31BBC Q38639973-CE7F7A90-BA95-4D2A-A699-D756DD197538 Q38694200-49C3CEB3-C2C6-43BA-BF71-7B8B22782044 Q38734731-0729F92A-3045-47B7-98F7-786462334EB8 Q38780801-40C8ADA7-2AEB-4DB4-B944-0DA05C9A6800 Q38870685-11CB7327-142B-4E92-BEFD-3D79F0AA5BC1 Q38939243-08EB1AFB-2168-44EF-9D81-0864C22D1566 Q38998576-D983B86B-E826-4E33-9541-22E1DBAE6B56

P2860

Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man study.

http://www.wikidata.org/entity/Q34209528

description

2011 nî lūn-bûn

@nan

2011 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Dose-dependent augmentation of ...... ecarbil: a first-in-man study.

@ast

Dose-dependent augmentation of ...... ecarbil: a first-in-man study.

@en

Dose-dependent augmentation of ...... ecarbil: a first-in-man study.

@nl

type

label

Dose-dependent augmentation of ...... ecarbil: a first-in-man study.

@ast

Dose-dependent augmentation of ...... ecarbil: a first-in-man study.

@en

Dose-dependent augmentation of ...... ecarbil: a first-in-man study.

@nl

prefLabel

Dose-dependent augmentation of ...... ecarbil: a first-in-man study.

@ast

Dose-dependent augmentation of ...... ecarbil: a first-in-man study.

@en

Dose-dependent augmentation of ...... ecarbil: a first-in-man study.

@nl

P1433

Q34209528-2218A5EA-07E9-409E-9885-5F2304AC839C

P1476

Q34209528-6060CBC7-519D-4D65-9367-69B229E8D278

P2093

Q34209528-008FC8FB-9C15-4E00-A70A-BE19D0B2E420

Q34209528-056386A0-62B3-402F-A412-8DFACA534E14

Q34209528-196597B6-BDA9-4682-862B-ABAD446F202A

Q34209528-3DA36101-1402-4B86-A8B6-B72B8CA70E80

Q34209528-423FA127-129F-4740-B8B3-CE0F76204347

Q34209528-66AE9E42-E7CD-43EF-966D-2FE9FAD9A06E

Q34209528-7AC2AD38-283F-4DA5-949C-D053292FC32D

Q34209528-82F996DB-107F-4FFC-B3EE-B1AD83CEEE9F

Q34209528-9440A22A-D81A-49E4-A683-F10A8B0ECE5F

Q34209528-A8B59EB7-0371-4ECB-86CA-827BA01CEE18

P304

Q34209528-539D1106-2940-4D8C-AE73-97B0549E03FC

P31

Q34209528-3486F630-31D3-4653-8F33-9DEC434F5EAE

P356

Q34209528-AFB89D81-7D59-4DD4-929E-0D081B8BDC7C

P407

Q34209528-56A29596-E896-4B3C-90DB-F41BC3830994

P433

Q34209528-43FB67A7-3FB8-47F3-BE7A-00D221699993

P478

Q34209528-053F4F2A-436F-4531-8E5B-627B2A037D58

P577

Q34209528-7082AE0D-0449-4720-856B-9B8609C25D75

P698

Q34209528-BF6F13A3-7591-4D77-9C88-8E3599D675CF

P921

Q34209528-734A6C74-87A7-4804-BAE9-5825B6F0C863

P356

S0140-6736(11)61219-1

P1433

P1476

Dose-dependent augmentation of ...... ecarbil: a first-in-man study.

@en

P2093

Andrew A Wolff

http://www.w3.org/2001/XMLSchema#string

Cyril P Clarke

http://www.w3.org/2001/XMLSchema#string

Fady I Malik

http://www.w3.org/2001/XMLSchema#string

Jacqueline H Lee

http://www.w3.org/2001/XMLSchema#string

John R Teerlink

http://www.w3.org/2001/XMLSchema#string

Jonathan H Goldman

http://www.w3.org/2001/XMLSchema#string

Khalil G Saikali

http://www.w3.org/2001/XMLSchema#string

Lyndsey Elliott

http://www.w3.org/2001/XMLSchema#string

Michael M Chen

http://www.w3.org/2001/XMLSchema#string

Mohammad Reza Habibzadeh

http://www.w3.org/2001/XMLSchema#string

P304

667-675

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/S0140-6736(11)61219-1

http://www.w3.org/2001/XMLSchema#string

P407

P433

9792

http://www.w3.org/2001/XMLSchema#string

P478

378

http://www.w3.org/2001/XMLSchema#string

P577

2011-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21856480

http://www.w3.org/2001/XMLSchema#string

P921